NEW
YORK, March 24, 2025 /PRNewswire/ -- Baird
Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or
the "Company") has been honored with the "Most Valuable Investment
Award" at the 10th China Medical Industry Innovation Competition,
recognizing its groundbreaking AI Tumor Ablation Surgical
Robot.
The China Medical Industry Innovation Competition is a premier
industry event recognizing cutting-edge medical technologies with
high investment potential. The competition highlights breakthrough
innovations poised to transform healthcare, with a focus on
advancing medical science and improving patient outcomes. This
award underscores Baird Medical's leadership in AI-driven tumor
ablation technology. The AI Tumor Ablation Surgical Robot is
designed to enhance precision, automation, and real-time
decision-making in microwave ablation (MWA), aiming to transform
interventional oncology.
"This recognition reaffirms our commitment to advancing
AI-powered surgical solutions," said Haimei Wu, Chairwoman of
Baird Medical. "We believe our innovation will set new standards
in tumor ablation, improving patient outcomes globally."
Baird Medical remains dedicated to accelerating the development
and commercialization of its AI Tumor Ablation Surgical Robot,
reinforcing its position in minimally invasive technology.
About Baird Medical
Baird Medical is a forward-thinking medical device company
specializing in minimally invasive diagnostics and treatment. It is
dedicated to the research and development of AI-powered surgical
robotic systems and innovative minimally invasive surgical
instruments. Our mission is to enhance patient outcomes through
precision technology and advanced diagnostic solutions. The
company's technological roadmap will fully integrate breakthrough
innovations from the open-source AI community—leveraging
cutting-edge inference models such as Deepseek and Grok3, while
fostering strategic collaborations with leading academic
institutions. Our vision extends beyond surgical assistance, aiming
to develop intelligent systems that proactively guide diagnostic
decisions and preventive healthcare strategies. As an FDA
510(k)-certified medical device company, Baird Medical has deployed
its solutions in over 30 prestigious hospitals and clinics across
the United States, including Johns
Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine,
and Columbia University Medical Center.
Baird Medical is also the market leader in China in thyroid microwave ablation devices
and consumables. Meanwhile, the company's minimally invasive
treatment products are gradually expanding their commercial
presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not
historical facts but are forward-looking statements for purposes of
the safe harbor provisions under the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally relate to future events or Baird Medical's
future financial or operating performance. In some cases, you can
identify forward-looking statements by terminology such as "may",
"could", "should", "expect", "intend", "might", "will", "estimate",
"anticipate", "believe", "budget", "forecast", "intend", "plan",
"potential", "predict", "potential" or "continue", or the negatives
of these terms or variations of them or similar terminology.
Forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Baird Medical and
its management, are inherently uncertain. New risks and
uncertainties may emerge from time to time, and it is not possible
to predict all risks and uncertainties. You should not place undue
reliance on forward-looking statements in this press release, which
speak only as of the date they are made and are qualified in their
entirety by reference to the cautionary statements herein. Baird
Medical does not undertake any duty to update these forward-looking
statements.
Actual results may vary materially from those expressed or
implied by forward-looking statements based on a number of factors,
including, without limitation: (1) the risk that Baird Medical may
not be successful in expanding its business in China or the United
States; (2) changes in general economic conditions; (3)
regulatory conditions and developments; (4) changes in applicable
laws or regulations; (5) the nature, cost and outcome of pending
and future litigation and other legal proceedings instituted
against Baird Medical or others; and (5) other risks and
uncertainties from time to time described in the Registration
Statement relating to the Business Combination and the transition
report, including those listed under the sections titled "Risk
Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional
information concerning certain of these and other risk factors is
contained in ExcelFin's most recent filings with the SEC and in the
Registration Statement described above filed by Baird Medical in
connection with its business combination with ExcelFin. All
subsequent written and oral forward-looking statements concerning
Baird Medical, the business combination described herein or other
matters attributable to Baird Medical or any person acting on its
behalf are expressly qualified in their entirety by the cautionary
statements above. Readers are cautioned not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. Baird Medical expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in their expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-wins-most-valuable-investment-award-for-ai-tumor-ablation-surgical-robot-302408896.html
SOURCE BDMD
